VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621
Recruiting
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2025
Locations: VYGR Site 840018, Los Angeles, California +24 locations
Conditions: Alzheimer's Disease (AD)
Register for Updates
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
NCT07009509
Recruiting
The goal of this pilot study is to determine the feasibility of a randomized trial of the YES-CAN! (Youth Engaged Strategies to Change Adolescent Norms) program to prevent nicotine vaping among adolescents. The program integrates the following evidence-based strategies: youth-adult collaboration; youth-developed narrative videos to convey health messages; peer leaders as change agents; and sustained implementation to change the normative environment. Two middle/high school communities will recei... Read More
Gender:
ALL
Ages:
Between 9 years and 89 years
Trial Updated:
05/29/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Nicotine Vaping
Register for Updates
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445
Recruiting
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/29/2025
Locations: Georgia Nephrology Research Inst, Lawrenceville, Georgia +38 locations
Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Register for Updates
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
NCT05372614
Recruiting
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +17 locations
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
Storytelling and Mindfulness for Graduate Student Wellbeing
NCT05826860
Recruiting
The purpose of this study is to evaluate an intervention for improving Science, Technology, Engineering, and Math (STEM) graduate student wellbeing. Participants will be recruited from the University of Wisconsin-Madison graduate student body. Data will be collected from participants for up to 2 years, and the investigators anticipate that the study will last for 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Wisconsin Institute for Discovery, Madison, Wisconsin
Conditions: Depression, Anxiety, Burnout, Student
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +74 locations
Conditions: Hidradenitis Suppurativa
Register for Updates
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978
Recruiting
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to furt... Read More
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
05/29/2025
Locations: Providence Medical Foundation, Fullerton, California +4 locations
Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
Register for Updates
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
NCT06469307
Recruiting
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Blood Cancer, Leukemia
Register for Updates
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212
Recruiting
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Miami, Miami, Florida +16 locations
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
NCT06877169
Recruiting
The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Register for Updates
Rise & Renew: Supporting Well-Being in Black Women After the Loss of a Loved One
NCT07009795
Recruiting
This study is testing a new grief support program called Rise \& Renew (Remembering, Expressing, Navigating, Embracing, Witnessing) designed for Black women ages 40 and older who have experienced the loss of a close loved one, such as a spouse or significant other, parent, or child (including pregnancies). The program includes a weekend wellness retreat followed by 10 weeks of online group support. Participants will be randomly assigned to start weekly virtual sessions right away or after a 10-w... Read More
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
05/29/2025
Locations: Serenity Haven, Lithonia, Georgia
Conditions: Bereavement, Grief, Psychological Distress, Well Being
Register for Updates
Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples
NCT04298255
Recruiting
The purpose of this research study is to evaluate if special types of cells called round spermatids can be gathered from men with non-obstructive azoospermia and used (in absence of elongated spermatids and spermatozoa) to reliably and effectively create pregnancy with a procedure called Round Spermatid Injection (ROSI). This process is similar to In Vitro Fertilization, or 'IVF'. In addition, this study wants to test the safety of ROSI and see what effects (good and bad) it has on embryo create... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Carolinas Fertility Institute (CFI), Winston-Salem, North Carolina
Conditions: Infertility, Male
Register for Updates